Dyne Therapeutics Statistics
Share Statistics
Dyne Therapeutics has 101.77M shares outstanding. The number of shares has increased by 63.58% in one year.
| Shares Outstanding | 101.77M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 2.57% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 77.62M |
| Failed to Deliver (FTD) Shares | 45 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 9.94M, so 9.77% of the outstanding shares have been sold short.
| Short Interest | 9.94M |
| Short % of Shares Out | 9.77% |
| Short % of Float | 12.91% |
| Short Ratio (days to cover) | 12.11 |
Valuation Ratios
The PE ratio is -3.36 and the forward PE ratio is -9.28.
| PE Ratio | -3.36 |
| Forward PE | -9.28 |
| PS Ratio | 0 |
| Forward PS | 4813.2 |
| PB Ratio | 8.7 |
| P/FCF Ratio | -4.2 |
| PEG Ratio | n/a |
Enterprise Valuation
Dyne Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 2.53, with a Debt / Equity ratio of 0.3.
| Current Ratio | 2.53 |
| Quick Ratio | 2.53 |
| Debt / Equity | 0.3 |
| Total Debt / Capitalization | 23.09 |
| Cash Flow / Debt | -6.86 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.58% and return on capital (ROIC) is -204%.
| Return on Equity (ROE) | -2.58% |
| Return on Assets (ROA) | -1.43% |
| Return on Capital (ROIC) | -204% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.36M |
| Employee Count | 173 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 102.76% in the last 52 weeks. The beta is 1.09, so Dyne Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.09 |
| 52-Week Price Change | 102.76% |
| 50-Day Moving Average | 30.57 |
| 200-Day Moving Average | 32.74 |
| Relative Strength Index (RSI) | 36.63 |
| Average Volume (20 Days) | 1.02M |
Income Statement
In the last 12 months, Dyne Therapeutics had revenue of $0 and earned -$235.94M in profits. Earnings per share was $-3.95.
| Revenue | 0 |
| Gross Profit | -2.46M |
| Operating Income | -242.16M |
| Net Income | -235.94M |
| EBITDA | -233.48M |
| EBIT | - |
| Earnings Per Share (EPS) | -3.95 |
Balance Sheet
The company has $121.63M in cash and $27.41M in debt, giving a net cash position of $94.21M.
| Cash & Cash Equivalents | 121.63M |
| Total Debt | 27.41M |
| Net Cash | 94.21M |
| Retained Earnings | -632.51M |
| Total Assets | 768.84M |
| Working Capital | 693.13M |
Cash Flow
In the last 12 months, operating cash flow was -$188.16M and capital expenditures -$729.00K, giving a free cash flow of -$188.89M.
| Operating Cash Flow | -188.16M |
| Capital Expenditures | -729.00K |
| Free Cash Flow | -188.89M |
| FCF Per Share | -3.16 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
DYN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -15.34% |
| FCF Yield | -7.21% |
Analyst Forecast
The average price target for DYN is $52, which is 101.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $52 |
| Price Target Difference | 101.9% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Scores
| Altman Z-Score | 22.87 |
| Piotroski F-Score | 4 |